• PDF / 169,389 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 66 Downloads / 129 Views

DOWNLOAD

REPORT

---

1 S

Erythema multiforme and off label use: 2 case reports In a report, an 82-year-old man and a 48-year-old man were described, who developed erythema multiforme (EM) following off label treatment with azithromycin, ceftriaxone, ertapenem, hydroxychloroquine or lopinavir/ritonavir for SARS-CoV-2 pneumonia [dosages and routes not stated; not all time to reactions stated]. Patient 1: The 82-year-old man, who was diagnosed with SARS-CoV-2 pneumonia, received off label treatment with hydroxychloroquine, ceftriaxone and ertapenem. Twelve days after completing the treatment, he developed EM with no systemic symptoms. He had erythematous to violaceous papules and plaques converging in his trunk with some lesions in target. He was treated with prednisone, following which EM resolved. Patient 2: The 48-year-old man, who was diagnosed with SARS-CoV-2 pneumonia, received off label treatment with hydroxychloroquine, lopinavir/ritonavir, ceftriaxone and azithromycin. Three weeks after the onset of respiratory symptoms, he developed EM with no accompanying symptoms. He had erythematous to violaceous papules and plaques converging in his trunk with some lesions in target. He was treated with prednisone, following which EM resolved. Sanchez-Velazquez A, et al. Erythema multiforme in the context of SARS-Coronavirus-2 infection. Medicina Clinica 155: 141, No. 3, 14 Aug 2020. Available from: URL: 803507316 http://doi.org/10.1016/j.medcli.2020.04.016 [Spanish; summarised from a translation]

0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 17 Oct 2020 No. 1826